TY - JOUR
T1 - The potential of gallic acid as a radiosensitizer on human prostate cancer
T2 - A systematic review of preclinical studies
AU - Cahyono, Agung Tri
AU - Louisa, Melva
AU - Mayang Permata, Tiara Bunga
AU - Handoko,
AU - Nuryadi, Endang
AU - Kodrat, Henry
AU - Wibowo, Heri
AU - Hariandy Hamid, Agus Rizal Ardy
AU - Sekarutami, Sri Mutya
AU - Gondhowiardjo, Soehartati Argadikoesoema
N1 - Publisher Copyright:
© 2021 UPM Press. All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Prostate adenocarcinoma accounts for majority of prostate cancer cases, and it was found to be highly radioresistant. Gallic acid is a phenolic acid naturally occurring in many plants, reported to exhibit biological activities in eliminating cancer cell lines and xenografts. The purpose of this study is to review gallic acid as a potential radiosensitizer agent in prostate cancer treatment. Article search was conducted in PubMed, EBSCO, and Scopus. 11 studies using different cell lines including DU145, PC-3, LNCaP, and 22Rv1 xenograft of human prostate cancer were reviewed in this paper. Gallic acid acts as a radiosensitizer mainly by increasing caspase-3 and caspase-9 activation resulting in apoptosis, while also reducing intracellular CDKs, cyclins, and cdc25 phosphatases ultimately causing G2-M cell cycle arrest. Gallic acid has a potential to be a new radiosensitizer compound in prostate cancer treatment. Additional clinical studies using gallic acid derivatives with lower hydrophilicity are needed.
AB - Prostate adenocarcinoma accounts for majority of prostate cancer cases, and it was found to be highly radioresistant. Gallic acid is a phenolic acid naturally occurring in many plants, reported to exhibit biological activities in eliminating cancer cell lines and xenografts. The purpose of this study is to review gallic acid as a potential radiosensitizer agent in prostate cancer treatment. Article search was conducted in PubMed, EBSCO, and Scopus. 11 studies using different cell lines including DU145, PC-3, LNCaP, and 22Rv1 xenograft of human prostate cancer were reviewed in this paper. Gallic acid acts as a radiosensitizer mainly by increasing caspase-3 and caspase-9 activation resulting in apoptosis, while also reducing intracellular CDKs, cyclins, and cdc25 phosphatases ultimately causing G2-M cell cycle arrest. Gallic acid has a potential to be a new radiosensitizer compound in prostate cancer treatment. Additional clinical studies using gallic acid derivatives with lower hydrophilicity are needed.
KW - Apoptosis
KW - Gallic acid
KW - Prostate cancer
KW - Radiobiology
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85104201486&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:85104201486
SN - 1675-8544
VL - 17
SP - 246
EP - 254
JO - Malaysian Journal of Medicine and Health Sciences
JF - Malaysian Journal of Medicine and Health Sciences
IS - 2
ER -
